[PDF][PDF] KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab

A Lievre, JB Bachet, V Boige, A Cayre… - Journal of clinical …, 2008 - researchgate.net
A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, O Bouché, B Landi…
Journal of clinical oncology, 2008researchgate.net
Purpose Cetuximab is efficient in advanced colorectal cancer (CRC). We previously showed
that KRAS mutations were associated with resistance to cetuximab in 30 CRC patients. The
aim of this study was to validate, in an independent larger series of 89 patients, the
prognostic value of KRAS mutations on response to cetuximab and survival.
Purpose
Cetuximab is efficient in advanced colorectal cancer (CRC). We previously showed that KRAS mutations were associated with resistance to cetuximab in 30 CRC patients. The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival.
researchgate.net